UC San Diego Health Begins Treating Multiple Myeloma with CAR T-cell Therapy
June 3, 2021
As the first designated medical center in San Diego certified to offer this type of immunotherapy, UC San Diego Health will begin treating patients this month.
Your search for “Cancer Immunotherapy” returned 121 results
Cancer Immunotherapy Might Benefit From Previously Overlooked Immune Players
September 20, 2018
…published September 20 in Cell, may help researchers improve cancer immunotherapies and predict which patients will respond best.
UC San Diego Health First in Region to Provide Novel Therapy for Melanoma
June 4, 2024
Breakthrough one-time cancer treatment option for select patients with metastatic melanoma and solid tumors now offered at UC San Diego Health.
New Precision Immunotherapy Clinic Matches Patients to Latest Cancer Therapies
October 17, 2019
…from Canada to Moores Cancer Center at UC San Diego Health every month to receive cancer treatment at the newly established Precision Immunotherapy Clinic. Photo by Yadira Galindo/UC San Diego Health New Precision Immunotherapy Clinic Matches Patients to Latest Cancer Therapies Using a personalized approach, Moores Cancer Center at UC…
Stem Cell-Derived Therapy Shows Promise Against Treatment-Resistant Liver Cancer
July 9, 2024
Discover research from UC San Diego showing how stem cell-derived therapy, targeting treatment-resistant liver cancer through genetically modified NK cells, offers promising new avenues for immunotherapy.
Boosting Immune Cell Memory to Improve Vaccines and Cancer Immunotherapy
August 28, 2017
…could be used to improve how well vaccines and immunotherapies work and how long they last.
UC San Diego Health Treats 1st Cancer Patient with Stem-Cell Derived Natural Killer Cells
April 1, 2019
Moores Cancer Center at UC San Diego Health treats the first patient treated for cancer with a human-induced pluripotent stem cell (iPSC)-derived cell therapy called FT500. Dan Kaufman collaborated with Fate Therapeutics to bring the iPSC-derived natural killer cell cancer immunotherapy to patients.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
December 1, 2016
Previous studies identified the Hippo pathway kinases LATS1/2 as a tumor suppressor, but new research led by University of California San Diego School of Medicine scientists reveals a surprising role for these enzymes in subduing cancer immunity. The findings could have a clinical role in improving efficiency of immunotherapy drugs.
How Chronic Inflammation Tips the Balance of Immune Cells to Promote Liver Cancer
November 8, 2017
…known to drive many cancers, especially liver cancer. Researchers have long thought that’s because inflammation directly affects cancer cells, stimulating their division and protecting them from cell death. But University of California San Diego School of Medicine researchers have now found that chronic liver inflammation also promotes cancer by suppressing…
Inhibiting Enzyme Helps Cancer Immunotherapy Work Better
August 3, 2020
UC San Diego researchers discovered that people with an inactive RNA-editing enzyme respond better to cancer immunotherapy, and inhibitors of the enzyme help mice with difficult-to-treat cancers live longer.
